Business Context and Reporting Period
Company: Nu Skin Enterprises, Inc.
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended March 31, 2026
Business Overview: Nu Skin develops and distributes premium beauty and wellness products globally through a direct selling model. The company operates through seven geographic Nu Skin segments and two Rhyz segments (Manufacturing and Rhyz Other). In Q1 2026, the company continued pre-market activities in India and began winding down its BeautyBio business.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $320.6 million | $364.5 million |
| Gross Profit | $214.5 million (66.9% margin) | $247.0 million (67.8% margin) |
| Operating Income | $4.0 million | $(9.9) million |
| Net Income | $1.8 million | $107.5 million |
| Diluted EPS | $0.04 | $2.14 |
| Cash from Operations | $(3.9) million | $0.4 million |
| Cash & Equivalents (End of Period) | $198.7 million | $203.8 million |
| Total Debt (Current + Long-term) | $223.6 million | $224.2 million |
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 12.0% year-over-year, driven by macroeconomic challenges, reduced consumer spending, and declines in Customers (-14%), Paid Affiliates (-8%), and Sales Leaders (-13%).
- Profitability Shift: Net income dropped significantly from $107.5 million to $1.8 million. The prior year included a $176.2 million pre-tax gain from the sale of the Mavely business, which was absent in Q1 2026.
- Impairment Charges: The company recorded $1.8 million in impairment expenses related to the decision to wind down the BeautyBio business, compared to $25.1 million in Q1 2025.
- Debt Restructuring: In March 2026, the company refinanced its debt, replacing the 2022 Credit Agreement with a new agreement featuring a $175 million term loan and a $75 million revolving facility. The leverage ratio covenant was tightened to 2.25:1.
- Operating Cash Flow: Operating cash flow turned negative ($3.9 million outflow) primarily due to prepaid corporate income taxes, compared to a slight positive flow in the prior year.
Guidance, Outlook, and Risks
- Strategic Priorities: Management is focused on business model optimization, the rollout of the Prysm iO intelligent wellness platform, and the full market opening in India anticipated in late 2026.
- Capital Expenditures: Estimated capital expenditures for 2026 are projected to be between $40 million and $60 million, focused on Rhyz plant expansion and IT systems.
- Dividends and Buybacks: The company declared a quarterly dividend of $0.06 per share. It repurchased $5.0 million of stock in Q1 2026, with $137.3 million remaining available under its repurchase plan.
- Risks: Key risks include continued macroeconomic headwinds affecting consumer spending, foreign currency fluctuations, regulatory challenges in various jurisdictions (including Mainland China and Argentina), and the execution of the transition to the new sales performance plan.
Investor Verification Checklist
- BeautyBio Exit: Verify the timeline and remaining costs associated with winding down the BeautyBio business.
- India Expansion: Monitor progress on the India market launch scheduled for late 2026 and associated pre-market costs.
- Debt Covenants: Confirm ongoing compliance with the new 2.25:1 leverage ratio covenant under the March 2026 Credit Agreement.
- Sales Force Trends: Track the stabilization of Paid Affiliate and Sales Leader counts following the recent declines.
- LifeDNA Strategy: Review management's evaluation of strategic opportunities for LifeDNA, including potential divestiture.